Evaluation of factors that affect the response to Etanercept and Adalimumab in treatment of Joint involvement in patients with Spondyloarthropathy and Rheumathoid Arthritis
Phase 2
- Conditions
- Condition 1: Rheumatoid Arthritis. Condition 2: Ankylosing spondylitis.Rheumatoid arthritis with rheumatoid factorAnkylosing spondylitis
- Registration Number
- IRCT20240309061221N1
- Lead Sponsor
- Hamedan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 148
Inclusion Criteria
All patients with a definitive diagnosis of rheumatoid arthritis or spondyloarthropathy who are candidates for receiving anti-TNF drugs.
Exclusion Criteria
The existence of contraindications for the administration of anti-TNF (history of MS, unexplained pancytopenia, heart failure class 2 and higher, presence of active infection, etc.)
The patient's unwillingness to cooperate
Inability to pay for medication
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method In Rheumatoid arthritis, DAS28 less than 3.3 is considered a response to treatment; In spondyloarthropathy, BASDAI above 4 is associated with high disease activity, and a decrease of 2 points after treatment is considered a response to treatment. Timepoint: 12 weeks after administration of the medication. Method of measurement: The response to treatment in patients with Rheumatoid arthritis is calculated using DAS-28 criteria and in Spondyloarthropathy patients using BASDAI criteria.
- Secondary Outcome Measures
Name Time Method